Show simple item record

dc.contributor.authorWard, MJ
dc.contributor.authorThirdborough, SM
dc.contributor.authorMellows, T
dc.contributor.authorRiley, C
dc.contributor.authorHarris, S
dc.contributor.authorSuchak, K
dc.contributor.authorWebb, A
dc.contributor.authorHampton, C
dc.contributor.authorPatel, NN
dc.contributor.authorRandall, CJ
dc.contributor.authorCox, HJ
dc.contributor.authorJogai, S
dc.contributor.authorPrimrose, J
dc.contributor.authorPiper, K
dc.contributor.authorOttensmeier, CH
dc.contributor.authorKing, EV
dc.contributor.authorThomas, GJ
dc.date.accessioned2017-03-29T14:17:07Z
dc.date.available2017-03-29T14:17:07Z
dc.date.issued2013-10-29
dc.date.submitted2017-01-21T08:19:08.887Z
dc.identifier.citationWard, M J et al. "Tumour-Infiltrating Lymphocytes Predict For Outcome In HPV-Positive Oropharyngeal Cancer". British Journal of Cancer 110.2 (2013): 489-500. Web. 29 Mar. 2017.en_US
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/22309
dc.description.abstractBACKGROUND: Human papillomavirus (HPV)-positive oropharyngeal cancer (OPSCC) is associated with improved survival compared with HPV-negative disease. However, a minority of HPV-positive patients have poor prognosis. Currently, there is no generally accepted strategy for identifying these patients. METHODS: We retrospectively analysed 270 consecutively treated OPSCC patients from three centres for effects of clinical, pathological, immunological, and molecular features on disease mortality. We used Cox regression to examine associations between factors and OPSCC death, and developed a prognostic model for 3-year mortality using logistic regression analysis. RESULTS: Patients with HPV-positive tumours showed improved survival (hazard ratio (HR), 0.33 (0.21-0.53)). High levels of tumour-infiltrating lymphocytes (TILs) stratified HPV-positive patients into high-risk and low-risk groups (3-year survival; HPV-positive/TIL(high)=96%, HPV-positive/TIL(low)=59%). Survival of HPV-positive/TIL(low) patients did not differ from HPV-negative patients (HR, 1.01; P=0.98). We developed a prognostic model for HPV-positive tumours using a 'training' cohort from one centre; the combination of TIL levels, heavy smoking, and T-stage were significant (AUROC=0·87). This model was validated on patients from the other centres (detection rate 67%; false-positive rate 5.6%; AUROC=0·82). INTERPRETATION: Our data suggest that an immune response, reflected by TIL levels in the primary tumour, has an important role in the improved survival seen in most HPV-positive patients, and is relevant for the clinical evaluation of HPV-positive OPSCC.en_US
dc.format.extent489 - 500
dc.languageeng
dc.language.isoenen_US
dc.publisherNature Publishing Groupen_US
dc.relation.ispartofBr J Cancer
dc.rightsCC-BY--NC-SA
dc.subjectAgeden_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectLymphocytes, Tumor-Infiltratingen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectOropharyngeal Neoplasmsen_US
dc.subjectPapillomaviridaeen_US
dc.subjectPapillomavirus Infectionsen_US
dc.subjectPrognosisen_US
dc.subjectRetrospective Studiesen_US
dc.titleTumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer.en_US
dc.typeArticleen_US
dc.rights.holder© 2013, Rights Managed by Nature Publishing Group
dc.identifier.doi10.1038/bjc.2013.639
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/24169344
pubs.issue2
pubs.organisational-group/Queen Mary University of London
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry/Institute of Dentistry
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry/Institute of Dentistry/Clinical & Diagnostic Oral Sciences
pubs.publication-statusPublished
pubs.volume110


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Return to top